Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Sep 14, 2023; 29(34): 5075-5081
Published online Sep 14, 2023. doi: 10.3748/wjg.v29.i34.5075
Table 1 Clinical and laboratory data of patients with primary biliary cholangitis

Early-stage (stages I + II; n = 48)
Stage III (n = 22)
Stage IV (n = 12)
P value
ALT53.5 (29.5-124.5) 54.0 (30.0-127.6)80.0 (42.8-127.4)0.639
AST53.5 (34.0-97.3)a68.5 (39.6-114.1)112.2 (81.1-136.3)0.009
TBA9.0 (3.6-36.4)a18.0 (7.0-45.1)28.2 (18.0-111.5)0.011
TBIL15.4 (11.2-27.8)a16.7 (13.7-24.2)a61.2 (28.1-114.3)0.002
DBIL5.2 (3.7-16.0)a8.7 (2.5-12.4)a42.3 (15.8-67.3)0.003
ALB42.1 (38.3-44.8)a39.3 (36.5-42.5)35.8 (30. 5-41.0)0.005
A/G1.2 (1.1-1.4)a1.0 (0.9-1.3)0.9 (0.7-1.1)0.001
ALP200.4 (117.8-414.0)a292.5 (162.0-421.3)463.5 (329.6-770.5)0.008
GGT289.0 (133.0-668.8)532.0 (326. 5-764.3)336.5 (264.0-648.0)0.070
CHO5.8 (4.6-6.9)6.2 (5.1-7.5)6.8 (4.9-7.0)0.509
TG1.3 (1.0-1.8)1.6 (1.2-2.1)a1.1 (0.8-1.5)0.019
IgG16.7 ± 4.617.6 ± 6.720.6 ± 7.90.056
IgA2.9 (2.1-3.3)3.5 (2.5-4.7)3.4 (2.4-4.4)0.031
IgM3.4 (1.8-5.1)3.7 (2.1-5.0)3.7 (1.9-6.8)0.967
C31.4 (1.2-1.6)1.6 (1.3-1.8)1.2 (1.0-1.7)0.126
C40.2 (0.2-0.3)0.2 (0.2-0.3)0.2 (0.2-0.3)0.963
Table 2 Autoantibody positive rate in patients with early-stage primary biliary cholangitis
Autoantibody
AMA
AMA-M2
Anti-sp100
Anti-gp210
Anti-SSA/Ro52
Anti-SSA/Ro60
ANA
n3222898234
%66.745.816.718.816.74.270.8
Table 3 Anti-nuclear antibody subtype positive rate in patients with early-stage primary biliary cholangitis
ANA
Cytoplasmic speckled
Fibrillar
Reticular
Discrete
Homogeneous
Centromere
Nuclear speckled
Nucleolar
Nuclear
n24267165010
%504.212.514.62.112.510.4020.8